RA
ACAD icon

Royce & Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Royce & Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Buy
+91,885
New +$2.02M 0.02% 590

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royce & Associates's ACAD Position: Q2 2026 in Review

Royce & Associates opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 91,885 shares worth $2.32M. The stake represents 0.02% of the portfolio and ranks #590 among its holdings.

352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Royce & Associates held 91,885 shares of Acadia Pharmaceuticals worth $2.32M as of Q2 2026.
  • Acadia Pharmaceuticals was a new Royce & Associates position in Q2 2026.
  • Acadia Pharmaceuticals made up 0.02% of Royce & Associates's portfolio in Q2 2026, its #590 holding.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.